Brief: Harbour BioMed's Monoclonal Antibody, Enters Global Phase 2 Trial For Asthma
23/07/2025 13:40
July 23 (Reuters) - Hbm Holdings Ltd 2142.HK: HBM9378/WIN378, A LONG-ACTING, FULLY HUMAN ANTI-TSLP ANTIBODY, ENTERS GLOBAL PHASE 2 POLARIS TRIAL FOR ASTHMA HBM HOLDINGS LTD - PHASE 2 TRIAL DATA FOR HBM9378/WIN378 EXPECTED MID-2026 HBM HOLDINGS LTD - WINDWARD BIO PLANS GLOBAL COPD TRIALS IN 2026 Source text: ID:nPn9xZqTDa Further company coverage: 2142.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study